ClinicalTrials.gg
CompletedNCT00111475Updated Jan 10, 2020Results posted

Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

A Phase 2 interventional study of Romiplostim and Placebo in Idiopathic Thrombocytopenic Purpura, sponsored by Amgen. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-01-10.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Jul 2002, registered May 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
19th of 29
45 · median 62
Started
2002
with 1 other
Phase 2
8 of 29
1 open now
Registered
3rd of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 19th largest by enrollment, is one of 2 that started in 2002, is one of 8 in phase 2, and was the 3rd registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with ITP.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura

Keywords

  • Immune Thrombocytopenic Purpura
  • Idiopathic Thrombocytopenic Purpura
  • Thrombocytopenic
  • Thrombocytopenia
  • ITP
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ITP according to American Society of Hematology (ASH) guidelines at least 3 months before enrollment
  • Have completed at least 1 prior treatment for ITP
  • Two (including day -2) of the 3 counts taken during the screening and pre-treatment periods must have fulfilled the following:

    • less than 30 x 10\^9/L for those subjects not receiving any ITP therapy,
    • less than 50 x 10\^9/L for those subjects receiving any ITP therapy
  • performance status of 0 to 2
  • Serum creatinine concentration ≤ 2 mg/dL (≤ 176.8 µmol/L)
  • Adequate liver function, as evidenced by a serum ≤ 1.5 times the laboratory normal range
  • greater than 10.0 g/dL
  • Written

Exclusion criteria

Exclusion Criteria:

  • Considered a substantial risk for adverse outcomes because of a trend (as determined by the investigator) detected in the counts during the screening period
  • Any known history of bone marrow stem cell disorder
  • Any active . If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, no treatment or active disease within 5 years before randomization
  • Documented diagnosis of arterial thrombosis (ie, stroke, , or myocardial infarction) in the previous year; history of venous thrombosis (ie, deep vein thrombosis, pulmonary embolism) and receiving anticoagulation therapy
  • Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure [ (NYHA) greater than class II], uncontrolled hypertension [diastolic greater than 100 mmHg] or cardiac arrhythmia)
  • Have 3 or more of the following predisposing factors for thromboembolic events: diabetes; smoker using oral ; hypercholesteremia (> 240 mg/dL); treatment for hypertension
  • Known positive test for (HIV) infection or virus
  • Received any treatment for ITP (except for a constant dose schedule of ) within 4 weeks before the screening visit
  • Received intravenous (IV) immunoglobulin (Ig) or WinRho within 2 weeks before the screening visit
  • Received hematopoietic growth factors, including interleukin (IL)-11 (Neumega®) within 4 weeks before the screening visit
  • Past or present participation in any study evaluating polyethylene glycol recombinant human magakaryopoiesis differentiating factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO), or related platelet product
  • Received any alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study
  • Received any monoclonal antibody (eg, rituximab) within 16 weeks before the screening visit or anticipated use during the time of the proposed study
  • Less than 4 weeks since receipt of any therapeutic drug or device that is not FDA approved for any indication before the screening period
  • Less than 2 months since major surgery (including laparoscopic splenectomy)
  • Pregnant or breast feeding
  • Subjects of who are not using adequate contraceptive precautions, in the judgment of the investigator
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Part A: Romiplostim 0.2 µg/kg

    Participants received 0.2 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.

    Drug: Romiplostim

  • Experimental
    Part A: Romiplostim 0.5 µg/kg

    Participants received 0.5 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.

    Drug: Romiplostim

  • Experimental
    Part A: Romiplostim 1.0 µg/kg

    Participants received 1.0 µg/kg romiplostim subcutaneously on day 1 and on day 15 or 22 depending on platelet counts.

    Drug: Romiplostim

  • Experimental
    Part A: Romiplostim 3 µg/kg

    Participants received 3.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.

    Drug: Romiplostim

  • Experimental
    Part A: Romiplostim 6 µg/kg

    Participants received 6.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.

    Drug: Romiplostim

  • Experimental
    Part A: Romiplostim 10 µg/kg

    Participants received 10.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.

    Drug: Romiplostim

  • Placebo comparator
    Part B: Placebo

    Participants received placebo subcutaneously once a week for 6 weeks.

    Drug: Placebo

  • Experimental
    Part B: Romiplostim 1.0 µg/kg

    Participants received 1.0 µg/kg subcutaneously once a week for 6 weeks.

    Drug: Romiplostim

  • Experimental
    Part B: Romiplostim 3.0 µg/kg

    Participants received 3.0 µg/kg subcutaneously once a week for 6 weeks.

    Drug: Romiplostim

  • Experimental
    Part B: Romiplostim 6.0 µg/kg

    Participants received 6.0 µg/kg subcutaneously once a week for 6 weeks.

    Drug: Romiplostim

Interventions

  • Administered by subcutaneous injection

    Also known as: AMG 531, NPLATE

  • DrugPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Time frame: From first dose of study drug through 8 weeks (Part A) or 6 weeks (Part B) after last dose of study drug; 78 days

  2. Number of Participants With Anti-romiplostim or Anti-endogenous Thrombopoietin Neutralizing Antibodies

    The development of antibodies to romiplostim or to endogenous thrombopoietin (eTPO) was assessed using a neutralizing bioassay. Participants positive for neutralizing antibodies at any of the assessments during the study are reported.

    Time frame: Assessed on day 29 (Part A only), day 43 (Part B only), and day 78

Secondary outcomes

  1. Number of Participants Who Achieved Targeted Therapeutic Platelet Level in Part A

    Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and between 50 to 450 x 10⁹ cells/L. Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

    Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)

  2. Number of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part A

    Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

    Time frame: After first dose (day 1 to day 15 or 22), and after second dose (day 15 or 22 to day 78)

  3. Number of Participants With a Peak Platelet Count ≥ 100 x 10⁹ Cells/L in Part A

    Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

    Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)

  4. Number of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part A

    Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

    Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)

  5. Peak Platelet Count After Each Dose in Part A

    Platelet count data after the use of rescue medication were not included.

    Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)

  6. Change From Baseline in Peak Platelet Count After Each Dose in Part A

    Platelet count data after the use of rescue medication were not included.

    Time frame: Baseline and after first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)

  7. Time to Peak Platelet Count After Each Dose in Part A

    Platelet count data after the use of rescue medication were not included.

    Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)

  8. Duration Within the Targeted Therapeutic Platelet Range In Part A

    Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and ≥ 50 and ≤ 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included.

    Time frame: After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)

  9. Percentage of Participants Who Achieved Targeted Therapeutic Platelet Level In Part B

    Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 x 10⁹ cells/L and less than or equal to 450 x 10⁹ cells/L. Platelet count data after use of rescue medication were not included in the analysis.

    Time frame: Day 1 to day 78

  10. Percentage of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part B

    Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.

    Time frame: Day 1 to day 78

  11. Percentage of Participants With a Peak Platelet Count of ≥ 100 x 10⁹ Cells/L in Part B

    Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.

    Time frame: Day 1 to day 78

  12. Percentage of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part B

    Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.

    Time frame: Day 1 to day 78

  13. Percentage of Participants With a Peak Platelet Count of > 500 x 10⁹ Cells/L in Part B

    Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.

    Time frame: Day 1 to day 78

  14. Peak Platelet Count in Part B

    Platelet count data after administration of rescue medication were not included in the analysis.

    Time frame: Day 1 to day 78

  15. Change From Baseline in Peak Platelet Count in Part B

    Platelet count data after administration of rescue medication were not included in the analysis.

    Time frame: Baseline and day 1 to day 78

  16. Time to Peak Platelet Count in Part B

    Platelet count data after administration of rescue medication were not included in the analysis. Time to peak platelet count was analyzed using the Kaplan-Meier method.

    Time frame: Day 1 to day 78

  17. Duration Within the Targeted Therapeutic Platelet Range in Part B

    Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 × 10⁹ cells/L and less than or equal to 450 × 10⁹ cells/L. Platelet count data after administration of rescue medication were not included in the analysis.

    Time frame: Day 1 to day 78

07

Results

Posted Jan 10, 2020

Participant flow

This study consisted of 2 parts. Part A (conducted from July 1, 2002 to October 13, 2003) was an open-label, dose-escalation trial with sequential cohorts of participants. Part B (conducted from October 6, 2003 to June 17, 2004) was a double-blind, placebo-controlled, parallel design study.

Participant flow — Overall Study
MilestonePart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kgPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Started4444444881
Completed4444434881
Not completed0000010000
Withdrew: Lost to follow-up0000010000

Outcome measures

PrimaryNumber of Participants With Adverse Events
Time frame:
From first dose of study drug through 8 weeks (Part A) or 6 weeks (Part B) after last dose of study drug; 78 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kgPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Any adverse event4444444881
Serious adverse events2000012010
Treatment-related adverse events0030111240
Treatment-related serious adverse events0000010010
Discontinuations due to adverse events0000000000
Deaths0000000000
PrimaryNumber of Participants With Anti-romiplostim or Anti-endogenous Thrombopoietin Neutralizing Antibodies

The development of antibodies to romiplostim or to endogenous thrombopoietin (eTPO) was assessed using a neutralizing bioassay. Participants positive for neutralizing antibodies at any of the assessments during the study are reported.

Time frame:
Assessed on day 29 (Part A only), day 43 (Part B only), and day 78
Reported as:
Count of participants · Participants
Number of Participants With Anti-romiplostim or Anti-endogenous Thrombopoietin Neutralizing Antibodies
ParticipantsPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kgPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Anti-romiplostim neutralizing antibodies0000000000
Anti-eTPO neutralizing antibodies0000000000
SecondaryNumber of Participants Who Achieved Targeted Therapeutic Platelet Level in Part A

Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and between 50 to 450 x 10⁹ cells/L. Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

Time frame:
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Targeted Therapeutic Platelet Level in Part A
ParticipantsPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kg
After first dose100111
After second dose100211
After both doses100111
SecondaryNumber of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part A

Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

Time frame:
After first dose (day 1 to day 15 or 22), and after second dose (day 15 or 22 to day 78)
Reported as:
Count of participants · Participants
Number of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part A
ParticipantsPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kg
After first dose111223
After second dose100311
After both doses100211
SecondaryNumber of Participants With a Peak Platelet Count ≥ 100 x 10⁹ Cells/L in Part A

Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

Time frame:
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Reported as:
Count of participants · Participants
Number of Participants With a Peak Platelet Count ≥ 100 x 10⁹ Cells/L in Part A
ParticipantsPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kg
After first dose100123
After second dose000211
After both doses000111
SecondaryNumber of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part A

Platelet count data after the use of rescue medication were not included; participants with no platelet count data were considered non-responders.

Time frame:
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Reported as:
Count of participants · Participants
Number of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part A
ParticipantsPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kg
After first dose000012
After second dose000000
After both doses000000
SecondaryPeak Platelet Count After Each Dose in Part A

Platelet count data after the use of rescue medication were not included.

Time frame:
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Reported as:
Mean · 1 × 10⁹ cells/L
Peak Platelet Count After Each Dose in Part A
1 × 10⁹ cells/LPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kg
After first dose123.0——163.0309.0 ± 202.2746.3 ± 611.9
After second dose65.0——140.5 ± 29.0244.0259.0
SecondaryChange From Baseline in Peak Platelet Count After Each Dose in Part A

Platelet count data after the use of rescue medication were not included.

Time frame:
Baseline and after first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Reported as:
Mean · 1 × 10⁹ cells/L
Change From Baseline in Peak Platelet Count After Each Dose in Part A
1 × 10⁹ cells/LPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kg
After first dose109.5——150.2289.3 ± 208.2725.5 ± 622.5
After second dose51.50——122.6 ± 21.78220.0231.7
SecondaryTime to Peak Platelet Count After Each Dose in Part A

Platelet count data after the use of rescue medication were not included.

Time frame:
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Reported as:
Median · days
Time to Peak Platelet Count After Each Dose in Part A
daysPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kg
After first dose10.0 (10 to 10)——11.0 (11 to 11)9.5 (8 to 11)15.0 (12 to 15)
After second dose10.0 (10 to 10)——11.0 (9 to 13)10.0 (10 to 10)11.0 (11 to 11)
SecondaryDuration Within the Targeted Therapeutic Platelet Range In Part A

Targeted therapeutic platelet level was defined as a platelet count that was double the baseline level and ≥ 50 and ≤ 450 × 10⁹ cells/L. Platelet count data after the use of rescue medication were not included.

Time frame:
After first dose (day 1 to day 15 or 22) and after second dose (day 15 or 22 to day 78)
Reported as:
Mean · days
Duration Within the Targeted Therapeutic Platelet Range In Part A
daysPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kg
After first dose5.0——8.011.010.0
After second dose3.0——3.5 ± 2.111.09.0
SecondaryPercentage of Participants Who Achieved Targeted Therapeutic Platelet Level In Part B

Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 x 10⁹ cells/L and less than or equal to 450 x 10⁹ cells/L. Platelet count data after use of rescue medication were not included in the analysis.

Time frame:
Day 1 to day 78
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Targeted Therapeutic Platelet Level In Part B
percentage of participantsPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Percentage of Participants Who Achieved Targeted Therapeutic Platelet Level In Part B2588380
SecondaryPercentage of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part B

Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.

Time frame:
Day 1 to day 78
Reported as:
Number · percentage of participants
Percentage of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part B
percentage of participantsPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Percentage of Participants With an Increase in Platelet Count of ≥ 20 x 10⁹ Cells/L Over Baseline in Part B5010075100
SecondaryPercentage of Participants With a Peak Platelet Count of ≥ 100 x 10⁹ Cells/L in Part B

Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.

Time frame:
Day 1 to day 78
Reported as:
Number · percentage of participants
Percentage of Participants With a Peak Platelet Count of ≥ 100 x 10⁹ Cells/L in Part B
percentage of participantsPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Percentage of Participants With a Peak Platelet Count of ≥ 100 x 10⁹ Cells/L in Part B256363100
SecondaryPercentage of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part B

Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.

Time frame:
Day 1 to day 78
Reported as:
Number · percentage of participants
Percentage of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part B
percentage of participantsPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Percentage of Participants With a Peak Platelet Count of > 450 x 10⁹ Cells/L in Part B0025100
SecondaryPercentage of Participants With a Peak Platelet Count of > 500 x 10⁹ Cells/L in Part B

Platelet count data after administration of rescue medication were not included in the analysis. Participants with no platelet count data were considered non-responders.

Time frame:
Day 1 to day 78
Reported as:
Number · percentage of participants
Percentage of Participants With a Peak Platelet Count of > 500 x 10⁹ Cells/L in Part B
percentage of participantsPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Percentage of Participants With a Peak Platelet Count of > 500 x 10⁹ Cells/L in Part B0025100
SecondaryPeak Platelet Count in Part B

Platelet count data after administration of rescue medication were not included in the analysis.

Time frame:
Day 1 to day 78
Reported as:
Mean · 1 × 10⁹ cells/L
Peak Platelet Count in Part B
1 × 10⁹ cells/LPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Peak Platelet Count in Part B80.8 ± 96.0134.5 ± 90.2240.9 ± 288.3520.0
SecondaryChange From Baseline in Peak Platelet Count in Part B

Platelet count data after administration of rescue medication were not included in the analysis.

Time frame:
Baseline and day 1 to day 78
Reported as:
Mean · 1 × 10⁹ cells/L
Change From Baseline in Peak Platelet Count in Part B
1 × 10⁹ cells/LPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Change From Baseline in Peak Platelet Count in Part B52.4 ± 92.9117.6 ± 88.3226.9 ± 284.1505.0
SecondaryTime to Peak Platelet Count in Part B

Platelet count data after administration of rescue medication were not included in the analysis. Time to peak platelet count was analyzed using the Kaplan-Meier method.

Time frame:
Day 1 to day 78
Reported as:
Median · days
Time to Peak Platelet Count in Part B
daysPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Time to Peak Platelet Count in Part B63 (27.5 to 78)18 (11.5 to 35.5)19 (11 to 35.5)21 (21 to 21)
SecondaryDuration Within the Targeted Therapeutic Platelet Range in Part B

Targeted therapeutic platelet level was defined as a doubling of baseline platelet counts and within the range of greater than or equal to 50 × 10⁹ cells/L and less than or equal to 450 × 10⁹ cells/L. Platelet count data after administration of rescue medication were not included in the analysis.

Time frame:
Day 1 to day 78
Reported as:
Median · weeks
Duration Within the Targeted Therapeutic Platelet Range in Part B
weeksPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
Duration Within the Targeted Therapeutic Platelet Range in Part B6.0 (6 to 6)3.0 (1 to 7)5.0 (1 to 7)4.0 (4 to 4)

Adverse events

Collected over From first dose of study drug through 8 weeks (Part A) or 6 weeks (Part B) after last dose of study drug; 78 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Romiplostim 0.2 µg/kg—2/4 (50%)4/4 (100%)
Part A: Romiplostim 0.5 µg/kg—0/4 (0%)4/4 (100%)
Part A: Romiplostim 1.0 µg/kg—0/4 (0%)4/4 (100%)
Part A: Romiplostim 3 µg/kg—0/4 (0%)4/4 (100%)
Part A: Romiplostim 6 µg/kg—0/4 (0%)4/4 (100%)
Part A: Romiplostim 10 µg/kg—1/4 (25%)4/4 (100%)
Part B: Placebo—2/4 (50%)4/4 (100%)
Part B: Romiplostim 1.0 µg/kg—0/8 (0%)8/8 (100%)
Part B: Romiplostim 3.0 µg/kg—1/8 (12.5%)8/8 (100%)
Part B: Romiplostim 6.0 µg/kg—0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kgPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
ThrombocytopeniaBlood and lymphatic system disorders0/40/40/40/40/41/40/40/81/80/1
VertigoEar and labyrinth disorders1/40/40/40/40/40/40/40/80/80/1
Cerebral haemorrhageNervous system disorders1/40/40/40/40/40/40/40/80/80/1
Haemorrhage intracranialNervous system disorders0/40/40/40/40/40/41/40/80/80/1
AsthmaRespiratory, thoracic and mediastinal disorders0/40/40/40/40/40/41/40/80/80/1
Deep vein thrombosisVascular disorders0/40/40/40/40/40/41/40/80/80/1
Rectal haemorrhageGastrointestinal disorders0/40/40/40/40/40/40/40/81/80/1
ContusionInjury, poisoning and procedural complications0/40/40/40/40/40/40/40/81/80/1
Vaginal haemorrhageReproductive system and breast disorders0/40/40/40/40/40/40/40/81/80/1
Most frequent other events
Showing 10 of 119
Most frequent other events
EventPart A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kgPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kg
DiarrhoeaGastrointestinal disorders0/40/41/40/40/40/41/40/82/81/1
Oral mucosal blisteringGastrointestinal disorders0/41/40/41/40/41/40/41/83/81/1
Fungal infectionInfections and infestations0/40/40/40/40/40/40/40/80/81/1
HeadacheNervous system disorders1/42/43/44/41/40/40/42/83/80/1
ContusionInjury, poisoning and procedural complications0/43/40/43/43/43/42/46/83/80/1
EcchymosisSkin and subcutaneous tissue disorders0/40/43/40/40/41/42/43/81/80/1
Gingival bleedingGastrointestinal disorders0/41/40/41/41/40/41/40/84/80/1
NauseaGastrointestinal disorders1/40/42/40/40/40/41/40/82/80/1
Rectal haemorrhageGastrointestinal disorders0/40/40/40/40/40/42/40/80/80/1
StomatitisGastrointestinal disorders0/40/40/40/41/40/42/41/81/80/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kgPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kgTotal
Part A43.5 ± 15.042.8 ± 11.142.5 ± 10.744.8 ± 18.241.3 ± 14.747.5 ± 14.5————43.7 ± 12.8
Part B——————53.0 ± 10.643.0 ± 15.047.4 ± 16.642.0 ± NA14.3 ± 49.0
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kgPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kgTotal
Female314432365132
Male130012123013
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kgPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kgTotal
White444433355136
Black00001101003
Hispanic00000012306
Plateleet Count
Plateleet Count(1 × 10⁹ cells/L)Part A: Romiplostim 0.2 µg/kgPart A: Romiplostim 0.5 µg/kgPart A: Romiplostim 1.0 µg/kgPart A: Romiplostim 3 µg/kgPart A: Romiplostim 6 µg/kgPart A: Romiplostim 10 µg/kgPart B: PlaceboPart B: Romiplostim 1.0 µg/kgPart B: Romiplostim 3.0 µg/kgPart B: Romiplostim 6.0 µg/kgTotal
Part A10.7 ± 2.7014.5 ± 12.59.06 ± 4.1913.4 ± 6.8112.6 ± 9.0018.4 ± 10.1————13.1 ± 7.93
Part B——————28.4 ± 17.716.9 ± 7.8614.0 ± 6.2015.0 ± NA17.9 ± 10.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017 Aug;102(8):1342-1351. doi: 10.3324/haematol.2016.161968. Epub 2017 Apr 14. PubMed 28411254 ↗
  • Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006 Oct 19;355(16):1672-81. doi: 10.1056/NEJMoa054626. Erratum In: N Engl J Med. 2006 Nov 9;355(19):2054. PubMed 17050891 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2002 to primary completion in Jun 2004, 23 months.

Results were first posted in Jan 2020, 15 years 6 months after primary completion.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2005
First posted
May 23, 2005
StartActual
Jul 1, 2002
Primary completionActual
Jun 17, 2004
CompletionActual
Jun 17, 2004
Results first posted
Jan 10, 2020
Last update
Jan 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00111475
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 23, 2005
Start date
Jul 1, 2002
Primary completion
Jun 17, 2004
Completion
Jun 17, 2004
Results posted
Jan 10, 2020
Last update
Jan 10, 2020

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion